AETHLON MEDICAL, INC. (NASDAQ:AEMD) Files An 8-K Regulation FD Disclosure
ITEM 7.01
| REGULATION FD DISCLOSURE. |
Today, June 21, 2017, Mr. James Joyce, Chief Executive Officer of
Aethlon Medical, Inc. (the Company), presented at the BIO
International Convention. This presentation highlights certain
significant and material events for the Company, including
release of data regarding virus capture from our most recently
concluded clinical study, as well as an update on planned
initiation of government programs. A link to the presentation may
be accessed on the Companys website under the investor relations
section of the website or at
http://ir.aethlonmedical.com/ir-calendar/detail/2993/2017-bio-international-convention.
The website address is www.aethlonmedical.com. No portion of the
website shall be deemed to be incorporated into this Current
Report on Form 8-K.
| ITEM 9.01 | FINANCIAL STATEMENTS AND EXHIBITS. |
(d) EXHIBITS
| EXHIBIT NO. | DESCRIPTION |
| 99.1 |
Presentation materials BIO International Convention June 21, 2017 |
AETHLON MEDICAL INC ExhibitEX-99.1 2 aethlon_ex9901.htm INVESTOR PRESENTATION Exhibit 99.1 Image of Ebola viruses exiting host cells – Courtesy of NIAID BIO I NTERNATIONAL C ONVENTION J IM J OYCE – C HAIRMAN ,…To view the full exhibit click here About AETHLON MEDICAL, INC. (NASDAQ:AEMD)
Aethlon Medical, Inc. is a medical device company focused on creating devices for cancer, infectious disease and other life-threatening conditions. The Company operates through two segments: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities. The Company’s lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications, the Hemopurifier targets the removal of circulating exosomes, which are released to promote cancer progression and to seed the spread of metastasis. Through its subsidiary, Exosome Sciences, Inc. (Exosome), the Company is also developing exosome-based product candidates to diagnose and monitor neurological disorders and cancer.
